The prognostic value of neuromedin U in patients with hepatocellular carcinoma

BMC Cancer

Table 5 Univariate and multivariate analyses of clinicopathologic parameters associated with overall survival

Clinical parameters	Univariate analysis			Multivariate analysis
Clinical parameters	HR	95% CI	P value	HR	95% CI	P value
Sex (male vs. female)	0.726	0.410–1.285	0.271
Age (yrs) (≤60 vs. >60)	0.991	0.661–1.484	0.964
HCC family history (yes vs. no)	0.710	0.313–1.609	0.412
HBsAg (positive vs. negative)	0.906	0.538–1.525	0.710
Cirrhosis (yes vs. no)	1.055	0.704–1.581	0.795
Tumor number (single vs. multiple)	2.545	1.808–3.582	<0.001
Tumor size (cm) (≤5 vs. >5)	2.818	1.894–4.192	<0.001
Major vascular invasion (yes vs. no)	2.869	1.967–4.184	<0.001
Edmondson grade (I + II vs. III + IV)	1.711	1.181–2.479	0.005	1.718	1.179–2.504	0.005
TNM stage (I + II vs. III + IV)	3.851	2.739–5.413	<0.001	3.303	2.320–4.702	<0.001
Child-Pugh class (A vs. B)	1.813	1.041–3.159	0.036
PLT count (×10⁹) (≥100 vs. <100)	2.254	1.103–4.603	0.026
TBIL (μmol/L) (<34.2 vs. ≥34.2)	1.394	0.787–2.470	0.255
ALT (U/L) (≤40 vs. >40)	1.517	1.001–2.299	0.049
AST (U/L) (≤37 vs. >37)	3.265	2.261–4.716	<0.001	2.407	1.628–3.559	<0.001
AFP (ug/L) (≤20 vs. >20)	1.329	0.887–1.992	0.168
NMU peri-tumor (low vs. high group)	1.691	1.211–2.361	0.002	1.541	1.092–2.175	0.014
NMU intra-tumor (low vs. high group)	1.229	0.879–1.720	0.228

Abbreviations: HR hazard ratio, CI confidence interval, HCC hepatocellular carcinoma, HBsAg hepatitis B surface antigen, TNM tumor-node- metastasis, PLT platelet, TBIL total bilirubin, ALT alanine aminotransferase, AST aspartate aminotransferase, AFP a-fetoprotein, NMU neuromedin U. It was considered to have significance when a value of p was < 0.05

ISSN: 1471-2407